Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

FDA grants 510(k) clearance to Asante's Pearl Insulin Pump

Asante Solutions, Inc., a medical device company focused on diabetes care, announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the company's Pearl Insulin Pump. Last month, the Pearl also received the CE Mark, a European proof of conformity that certifies the product meets EU safety, health and environmental requirements.

17 May 2011

PKC-delta enzyme critical for development of insulin resistance, diabetes and fatty liver

The road to type 2 diabetes is paved with insulin resistance, a condition often associated with obesity in which the hormone begins to fail at its job helping to convert sugars to energy.

17 May 2011

High IGF-I hormone levels linked with better long-term recovery after stroke

Insulin-like growth factor I, IGF-I, is a hormone that is found in the blood and contributes to, among other things, growth and bone mass. The levels of this hormone are higher in people who exercise regularly and those with good health. Scientists at the Sahlgrenska Academy have shown for the first time that high levels of this hormone are associated with better long-term recovery after a stroke.

17 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Study reveals role of KLF14 regulatory gene in type 2 diabetes

A team of researchers, led by King's College London and the University of Oxford, have found that a gene linked to type 2 diabetes and cholesterol levels is in fact a 'master regulator' gene, which controls the behaviour of other genes found within fat in the body.

16 May 2011

Study reveals crucial role of histone deacetylases in type 2 diabetes

A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.

16 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Spouse caregivers may have high risk of cognitive impairment or dementia

An older individual who cares for a spouse with dementia may be at an increased risk of developing cognitive problems because of the lifestyle that was shared with the spouse and because of the stress of caring for a loved one who is ill.

13 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes.

11 May 2011

Independent investigator begins pump trial of Biodel's two ultra-rapid human insulin formulations

Biodel Inc. announced today that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations of recombinant human insulin.

10 May 2011

Abbott receives CE Mark approval for new blood glucose monitoring system

Abbott today announced that it has received CE Mark for its new FreeStyle InsuLinx Blood Glucose Monitoring System, the first blood glucose monitoring device from Abbott that includes a mealtime insulin calculator for calculating suggested insulin doses.

10 May 2011

Medtronic, Bayer HealthCare expand global alliance to develop next generation diabetes management solutions

Medtronic, Inc. and Bayer HealthCare have expanded their international alliance to now include the United States and will work exclusively to develop innovative next generation diabetes management solutions for patients, state-of-the-art, wireless blood glucose meters worldwide.

From Medtronic 9 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

Novel neurotransmitter could fight against neurological diseases

A team of scientists has discovered that D-aspartic acid is a novel neurotransmitter that could potentially be used in the fight against neurological diseases such as Parkinson's and schizophrenia.

6 May 2011

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

Breakthrough research offers hope for new obesity treatment

By knocking down the expression of a protein in rat brains known to stimulate eating, Johns Hopkins researchers say they not only reduced the animals' calorie intake and weight, but also transformed their fat into a type that burns off more energy. The finding could lead to better obesity treatments for humans, the scientists report.

4 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

McMaster receives new Canadian Cancer Society grants for groundbreaking research

Three cancer studies led by Hamilton researchers are among 52 new research projects worth close to $22 million announced by the Canadian Cancer Society.

3 May 2011

Insulin News and Research

Further Reading

FDA grants 510(k) clearance to Asante's Pearl Insulin Pump

PKC-delta enzyme critical for development of insulin resistance, diabetes and fatty liver

High IGF-I hormone levels linked with better long-term recovery after stroke

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Study reveals role of KLF14 regulatory gene in type 2 diabetes

Study reveals crucial role of histone deacetylases in type 2 diabetes

China's SFDA approves TPI anti-diabetic drug Gliclazide

Spouse caregivers may have high risk of cognitive impairment or dementia

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Independent investigator begins pump trial of Biodel's two ultra-rapid human insulin formulations

Abbott receives CE Mark approval for new blood glucose monitoring system

Medtronic, Bayer HealthCare expand global alliance to develop next generation diabetes management solutions

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Novel neurotransmitter could fight against neurological diseases

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

Breakthrough research offers hope for new obesity treatment

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

McMaster receives new Canadian Cancer Society grants for groundbreaking research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News